Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1547)	2/28/2002 3:22:45 AM
From: mopgcw	Read Replies (1) \| Respond to of 7143

Celltech Sees "Promising" Crohn's Disease Data DOW JONES NEWSWIRES Edited Press Release LONDON -- Celltech Group announces Thursday outline results showing promising efficacy and safety, from a large Phase II study with CDP 870 in Crohn's disease patients. Statistically significant clinical responses were noted as early as week two, and were maintained at most timepoints during the treatment period. The highest response rates were seen in the group treated with the highest dose, 400 milliong per month, with a maximal response rate of 54% versus 29% in the placebo group (p = 0.002), although the response rate at the individual 12 week timepoint did not reach significance, due to a marked increase in the placebo response rate. The potential of CDP 870 for disease management over an extended period was also assessed in this study. The overall response across the entire 12 week treatment period was statistically significantly greater for the 400 milliong group (p = 0.028) than placebo, when assessed by comparing the AUCs (areas under the curves). In this trial CDP870 was well tolerated, and no safety issues were identified. There were no notable differences among treatment groups, including placebo, in the number of patients reporting side effects. Phase III studies of CDP870 in Crohn's disease are expected to be initiated by Celltech during 2002. Dr. Peter Fellner, Chief Executive Officer of Celltech, commented: "These encouraging results provide us with confidence in proceeding to late-stage clinical studies with CDP870 in Crohn's disease".